TeraPore Technologies, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
TeraPore Technologies, Inc. - overview
Established
2013
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
TeraPore Technologies, Inc. is a US-based company specializing in advanced nanofiltration solutions, particularly in robust virus filtration for therapeutic protein purification and semiconductor manufacturing. TeraPore Technologies, Inc. was founded in 2013 and is headquartered in South San Francisco, US.
The company focuses on developing nanofiltration technologies and has successfully completed 3 funding deals, with the most recent in March 2023. The latest funding round, Series B, raised USD 10. 000 mn led by Anzu Partners, with participation from Entegris, Inc. and RA Capital Management.
With a current valuation of USD 44. 687 mn, CEO and founder Rachel Dorin leads the company, building on her previous entrepreneurial experiences. TeraPore Technologies specializes in advanced nanofiltration solutions, focusing on its flagship product, the IsoBlock® VF, designed for virus filtration in therapeutic protein purification and semiconductor manufacturing. Utilizing self-assembled block copolymer technology, IsoBlock® VF offers broad compatibility and consistent performance under challenging conditions, such as gamma irradiation.
Its isoporous membrane structure ensures high parvovirus retention and predictable filtration outcomes, targeting clients in the biopharmaceutical and semiconductor sectors, primarily in North America, Europe, and Asia. TeraPore Technologies generates revenue through the sale of its sophisticated filtration products, particularly the IsoBlock® VF, to businesses in the biopharmaceutical and semiconductor manufacturing sectors. The company employs a B2B transaction model, focusing on direct sales to manufacturers and laboratories that require high-performance filtration solutions, with both one-time purchases and ongoing partnerships that support recurring product procurement. The pricing structure reflects the premium nature of its technology, emphasizing the specialized applications and high value delivered to clients.
In March 2023, TeraPore Technologies, Inc. raised USD 10. 000 mn in funding to support its expansion into new areas with its precise nanofiltration technologies. The company is actively designing new products to enhance its offerings and is targeting specific markets for expansion, although the details of these markets and timelines have not been disclosed.
The recent funding will play a crucial role in facilitating these initiatives and driving the company's growth.
Current Investors
Anzu Partners, Artiman Ventures, RA Capital Management
Primary Industry
Biotechnology
Sub Industries
Bioinformatics
Website
www.teraporetech.com
Verticals
Nanotechnology
Company Stage
Series B
Total Amount Raised
Subscriber access only
TeraPore Technologies, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.